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Decreased	 left	 ventricular	 (LV)	 diastolic	 function	 is	 associated	with	 increased	 all-	
cause	mortality	and	risk	for	a	heart	failure.	The	determinants	of	LV	diastolic	function	
have	been	mainly	studied	in	elderly	populations;	however,	the	origin	of	LV	heart	fail-
ure	may	relate	to	the	lifestyle	factors	acquired	during	the	life	course.	Therefore,	we	
examined	biochemical,	physiological,	and	lifestyle	determinants	of	LV	diastolic	func-
tion	in	34–49-	year-	old	participants	of	the	Cardiovascular	Risk	in	Young	Finns	Study	
(Young	Finns	Study).	In	2011,	clinical	examination	and	echocardiography	were	per-
formed	for	1928	participants	(880	men	and	1048	women;	aged	34–49	years).	LV	di-
astolic	 function	was	primarily	defined	using	E/é-	ratio	 (population	mean	4.8,	 range	
2.1–9.0).	 In	 a	 multivariate	 model,	 systolic	 blood	 pressure	 (P	<	0.005),	 female	 sex	
(P	<	0.005),	 age	 (P	<	0.005),	 waist	 circumference	 (P	=	0.024),	 smoking	 (P	=	0.028),	
serum	alanine	aminotransferase	(P	=	0.032)	were	directly	associated	with	E/é-	ratio,	
while	an	inverse	association	was	found	for	height	(P	<	0.005).	Additionally,	a	higher	
E/é-	ratio	was	found	in	participants	with	concentric	hypertrophy	compared	to	normal	
cardiac	geometry	(P	<	0.005).	Other	indicators	of	the	LV	diastolic	function	including	
E/A-	ratio	and	left	atrial	volume	index	showed	similarly	strong	associations	with	sys-
tolic	 blood	pressure	 and	 age.	 In	 conclusion,	we	 identified	 systolic	 blood	pressure,	
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1  | INTRODUC TION
Heart	failure	with	preserved	ejection	fraction	is	one	of	the	main	car-
diac	disorders	with	rising	prevalence	 in	developed	countries.1	This	
condition	is	a	clinical	syndrome	characterized	by	symptoms	of	heart	
failure	with	 preserved	 LV	 systolic	 function	 but	 decreased	 LV	 dia-
stolic	 function,	 including	prolonged	 isovolumic	LV	 relaxation,	 slow	
LV	filling,	and	increased	diastolic	LV	stiffness.2,3	As	LV	diastolic	func-
tion	is	already	considerably	decreased	when	the	symptoms	of	heart	
failure	appear,	it	is	of	interest	to	characterize	the	determinants	of	LV	
diastolic	function	in	healthy	populations.	With	improved	knowledge	
on	the	determinants	of	LV	diastolic	function,	targeted	lifestyle	inter-
vention	could	be	focused	earlier	on	individuals	with	increased	risk	of	
LV	diastolic	dysfunction.
In	 previous	 studies	 among	 elderly	 populations,	 hypertension,	
obesity,	 diabetes,	 ventricular	 remodeling,	 and	 high	 age	 have	 been	
found	 to	 associate	 with	 worse	 LV	 diastolic	 dysfunction.3,4	 Even	
though	 the	 origins	 of	 decreased	 LV	 diastolic	 function	 in	 later	 life	
are	suggested	to	stem	from	lifestyle	factors	exerting	their	influence	
during	 the	whole	 life	 course,	 the	 links	between	 these	 factors	 and	
LV	diastolic	 function	 in	clinically	healthy	adult	population	have	re-
mained	obscure.	To	address	this	paucity	of	knowledge,	we	identified	
the	 determinants	 of	 LV	 diastolic	 function	 leveraging	 the	 echocar-
diographic,	 biochemical,	 physiological,	 and	 lifestyle	 data	 collected	
from	the	34-	to	49-	year-	old	participants	of	the	Cardiovascular	Risk	
in	Young	Finns	Study	(YFS).
2  | METHODS
Young	 Finns	 Study	 is	 an	 ongoing	 longitudinal	 population-	based	
study	on	cardiovascular	risk	factors	from	childhood	to	adulthood.5 
The	study	population	is	representative	of	the	general	Finnish	popu-
lation.	The	baseline	study	including	3596	children	and	adolescents	
(boys	and	girls;	aged	3,	6,	9,	12,	15	and	18	years)	was	conducted	in	
1980.	Extensive	data	on	cardiovascular	risk	factors	were	recorded	
at	baseline	and	in	all	follow-	up	studies	performed	regularly	in	1983,	
1986,	1989,	2001,	2007,	and	2011.	The	study	protocol	was	approved	
by	 the	ethics	 committee	of	 the	University	of	Turku,	 and	 informed	
consent	was	obtained	from	all	participants.	Detailed	information	on	
the	YFS	population	and	the	study	protocol	has	been	reported	ear-
lier.5	All	authors	had	full	access	to	the	data.
Echocardiography	was	performed	 in	2011	 for	N	=	1994	partic-
ipants	according	to	the	 joint	American	and	European	guidelines.2,6 
After	excluding	 the	participants	with	missing	LV	diastolic	 function	
measurements,	 severe	 cardiovascular	 diseases	 (including	 stroke,	
myocardial	 infarction,	 atrial	 fibrillation,	 unstable	 angina	 pecto-
ris,	 cardiomyopathies,	 and	 regurgitation	 or	 stenosis	 of	 mitral	 or	
aortic	 valve),	 the	 study	population	of	 the	 present	 study	 consisted	
of	 N	=	1928	 participants	 (880	 men	 and	 1048	 women,	 mean	 age	
41.9	±	5.0	years,	range	34–49	years).	Population	characteristics	are	
shown	in	detail	in	Table	S1.
Trained	 sonographers	performed	 the	echocardiographic	exam-
inations	 at	 five	 YFS	 study	 centers	 in	 Finland.	 Transthoracic	 echo-
cardiography	 was	 performed	 with	 Acuson	 Sequoia	 512	 (Acuson,	
Mountain	View,	CA)	ultrasonography,	using	3.5	MHz	scanning	fre-
quency	phased-	array	transducer.	All	sonographers	were	trained	by	
a	single	cardiac	imaging	specialist.	Analysis	of	the	echo	images	was	
performed	by	one	observer	blinded	to	the	clinical	details	with	the	
CommPACS	 10.7.8	 (MediMatic	 Solutions,	 Genova,	 Italy)	 analysis	
program.7	We	included	the	study	center	as	a	technical	covariate	in	
the	 statistical	models	 to	ensure	 that	 the	 results	 are	not	driven	by	
differences	between	the	centers.
E/é-	ratio,	 a	 noninvasive	 measurement	 representing	 LV	 filling	
pressure	 in	 early	 diastole,	was	used	 as	 an	 indicator	of	 LV	diastolic	
function	in	the	present	study.	Pulsed-	wave	Doppler	imaging	was	used	
to	measure	E	and	pulsed-	wave	 tissue	Doppler	 imaging	 to	measure	
é;	E	wave	describes	the	mitral	blood	flow	during	the	early	filling	of	
the	LV,	and	é	measures	mitral	annular	early	diastolic	velocity	toward	
left	atrium	(LA).	In	the	present	study,	E/é-	ratio	was	calculated	using	
the	average	of	lateral	and	septal	values	of	é	velocity.2	High	E/é-	ratio	
reflects	lower	LV	diastolic	function,	due	to	deterioration	of	LV	relax-
ation.	Moreover,	E/A-	ratio,	as	well	as	left	atrial	volume	index	(LAVi)	
were	defined	as	additional	indicators	of	LV	diastolic	function.	In	E/A-	
ratio,	A	wave	describes	the	mitral	blood	flow	during	the	late	filling	of	
the	LV	at	the	time	of	LA	contraction.	LA	volume	was	planimetered	
from	the	apical	four	chamber	view.	LAVi	was	calculated	as	“LA	vol-
ume/body	surface	area	(BSA),”	for	which	BSA	was	calculated	using	
Du	Bois	formula	(BSA	=	0.007184	×	weight0.425	×	height0.725).8
Left	 ventricular	 mass	 was	 calculated	 as	 (0.8[1.04((LV	 end-	
diastolic	 diameter	+	end-	diastolic	 posterior	 wall	 thickness	+	end-	
diastolic	 inter-	ventricular	 septum	 thickness)3	–	LV	 end-	diastolic	
diameter)3]	+	0.6	g.	 Relative	 wall	 thickness	 was	 calculated	 as	 (2×	
end-	diastolic	 posterior	 wall	 thickness)/LV	 end-	diastolic	 diameter.	
The	LV	geometry	groups	were	defined	by	the	population	85th	per-
centile	 cut-	offs	 values	 for	 LV	hypertrophy	 (indexed	 LV	mass/BSA)	
and	relative	wall	thickness.	Concentric	remodeling	is	defined	as	high	
relative	wall	thickness	without	LV	hypertrophy.	Eccentric	hypertro-
phy	 is	defined	as	 LV	hypertrophy	without	high	 relative	wall	 thick-
ness.	Concentric	hypertrophy	is	defined	as	LV	hypertrophy	with	high	
waist	circumference	and	smoking	as	modifiable	determinants	of	the	LV	diastolic	func-
tion	in	the	34–49-	year-	old	participants	of	the	Young	Finns	Study.
K E Y W O R D S
echocardiography,	left	ventricular	function,	left	ventricular	remodeling
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relative	wall	thickness.	The	intra-	class	correlation	coefficients	with	
5th	and	95th	percentile	confidence	intervals	and	coefficient	of	vari-
ance	have	been	reported	earlier	together	with	the	complete	meth-
odology	of	the	cardiac	imaging,	and	the	offline	analysis	of	the	cardiac	
measurements	conducted	in	the	YFS.7
Data	on	daily	smoking	(no/yes),	leisure-	time	physical	activity	(an	
index	 ranging	 between	 5–15),	 and	 alcohol	 consumption	 (standard	
drinks/day)	 were	 collected	 using	 questionnaires.9	 Using	 the	 data	
from	the	follow-	up	studies	 in	2001,	2007	and	2011,	diabetes	mel-
litus	was	defined	as	 (a)	 fasting	serum	glucose	over	7.0	mmol/L,	 (b)	
hemoglobin	A1c	over	6.5%,	(c)	use	of	insulin	or	per	oral	antidiabetic	
agents,	or	(d)	a	previous	diagnosis	of	diabetes	mellitus.
Heart	 rate	was	 reported	directly	 from	the	electrocardiography	
readings.	Blood	pressure	was	measured	using	a	random	zero	sphyg-
momanometer.	Hypertension	was	defined	as	(a)	systolic	blood	pres-
sure	>	140	mm	Hg,	or	(b)	diastolic	blood	pressure	>	90	mm	Hg,	or	(c)	
using	antihypertensive	medication.10	Harmonized	definition	was	used	
for	the	metabolic	syndrome:	(a)	waist	≥	102	cm	in	men	and	≥	88	cm	
in	women,	(b)	fasting	serum	glucose	≥	5.6	mmol/L	or	treatment	for	
diabetes	 mellitus,	 (c)	 hypertriglyceridemia	≥	1.7	mmol/L	 and	 high-	
density	 lipoprotein	cholesterol	 (HDL-	C)	 levels	<	1.0	mmol/L	in	men	
and	<	1.3	 in	 women	 and	 (d)	 blood	 pressure	≥	130/≥85	mm	Hg	 or	
treatment	for	hypertension.	A	diagnosis	of	the	metabolic	syndrome	
required	having	≥3	of	the	5	criteria.11	The	use	of	prescription	med-
ications	was	queried	from	the	participants	and	confirmed	from	the	
electronic	Patient	Data	Repository	of	Social	Insurance	Institution	of	
Finland.
Height,	 weight	 and	 waist	 circumference	 were	 measured	
during	each	study	visit.	Body	mass	index	(BMI)	was	calculated	as	
weight	 (kg)/height	 (m)2.	Venous	blood	samples	were	drawn	after	
an	overnight	fast	and	serum	was	separated,	aliquoted,	and	stored	
at	−70°C	until	analysis.	C-	reactive	protein	 (CRP)	was	determined	
immunoturbidimetrically.12	 The	 concentration	 of	 serum	 insu-
lin	was	 determined	with	 an	 immunoassay.12	 Homeostasis	model	
assessment-	estimated	insulin	resistance	(HOMA-	IR)	was	calculated	
as	(insulin	×	fasting	serum	glucose)/22.5.13	Fasting	serum	glucose,	
alanine	 aminotransferase	 (ALT),	 gamma-	glutamyltransferase	
(GGT),	 total	 cholesterol,	 HDL-	C,	 and	 triglyceride	 concentrations	
were	 measured	 by	 enzymatic	 methods.12	 Low-	density	 lipopro-
tein	 cholesterol	 (LDL-	C)	 concentration	 was	 calculated	 using	 the	
Friedewald's	formula	in	subjects	with	triglycerides	<	4.0	mmol/L.14 
Serum	creatinine	was	determined	spectrophotometrically	with	the	
Jaffe’	method.15	Glomerular	filtration	rate	was	counted	using	the	
Chronic	 Kidney	 Disease	 Epidemiology	 Collaboration	 equation.16 
The	 detailed	 descriptions	 of	 the	 determinants	 and	 biochemical	
analyses	have	been	published	earlier.5,7,12
2.1 | Statistical methods
Kolmogorov-	Smirnov	test	and	visual	evaluation	were	used	to	con-
firm	the	distributions	of	 the	study	variables.	Due	to	skewed	dis-
tributions,	values	for	ALT,	GGT,	CRP,	 triglycerides,	 fasting	serum	
glucose,	insulin,	and	HOMA-	IR	were	log-	transformed.	To	study	the	
differences	between	men	and	women,	a	Welch	Two	Sample	t	test	
was	used	for	each	continuous	variable	with	a	normal	distribution,	
while	 an	 independent	 2-	group	 Mann-	Whitney	 U-	Test	 was	 used	
for	 continuous	 variables	with	 skewed	 distribution.	 For	 categori-
cal	 variables,	 a	Pearson's	 chi-	squared	 test	with	Yates’	 continuity	
correction	 was	 used.	 Age,	 sex	 and	 study	 center	 adjusted	 mean	
E/é-	ratio	was	calculated	for	each	cardiac	remodeling	group	using	
least-	squares	means	(The	R	Package	lsmeans).17	Pearson's	correla-
tion	analysis	was	used	to	analyze	correlations	between	E/é-	ratio,	
conventional	cardiac	structure	measurements,	and	systolic	 func-
tion	measurements.
Linear	regression	analyses	were	conducted	to	study	the	associa-
tions	between	the	biochemical,	physiological,	and	lifestyle	determi-
nants	and	LV	diastolic	function.	First,	sex-	stratified	univariate	linear	
regression	analyses	adjusted	 for	 study	center	 (as	a	 technical	 cate-
gorical	variable	1–5)	were	conducted	separately	 for	each	determi-
nant	to	study	their	associations	for	E/é-	ratio.	Second,	a	multivariate	
linear	regression	model	for	E/é-	ratio	was	conducted	by	additionally	
including	sex,	age,	LV	mass,	systolic	blood	pressure,	height,	waist	cir-
cumference,	glomerular	filtration	rate,	ALT,	total	cholesterol,	fasting	
serum	glucose,	smoking,	alcohol	consumption,	and	physical	activity	
as	dependent	variables.
The	 possible	 effect	modification	 by	 sex	was	 analyzed	 by	 add-
ing	interaction	terms	(sex	*	age	and	sex	*	systolic	blood	pressure)	in	
the	multivariate	linear	regression	model.	No	significant	interactions	
were	found	(interaction	P-	values	always	>0.05).	Therefore,	the	inter-
action	terms	were	excluded	from	the	multivariate	linear	regression	
model.	A	 similar	multivariate	model	was	 conducted	 separately	 for	
E/A-	ratio	 and	LAVi	 (due	 to	 collinearity,	height	 and	waist	were	not	
included	in	the	model	for	LAVi).	The	level	of	statistical	significance	
was	set	at	P	˂	0.05.	We	used	all	available	data	(Table	S1)	in	the	analy-
ses.	Therefore,	the	number	of	participants	varies	between	the	mod-
els.	The	data	were	analyzed	using	the	R	statistical	package,	version	
3.3.2.	 (R	Core	Team	2016.	R:	A	language	and	environment	for	sta-
tistical	computing,	R	Foundation	for	Statistical	Computing,	Vienna,	
Austria,	http://www.R-project.org/).
F IGURE  1 Mean	E/é-	ratio	in	different	age	groups	in	men	and	
women.	Ribbons	denote	95%	confidence	intervals
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3  | RESULTS
The	 characteristics	 of	 the	 study	 population	 are	 described	 in	
Table	S1.	The	prevalence	of	obesity	 (BMI	>	30)	 in	 the	 study	pop-
ulation	 was	 20%.	 In	 the	 whole	 population,	 the	 E/é-	ratio	 values	
ranged	 between	 2.1	 and	 9.0,	 with	 a	 mean	 value	 of	 4.8.	Women	
had	 higher	 E/é-	ratio	 than	men	 (5.0	±	1.0	 vs	 4.6	±	0.9;	P	<	0.005).	
Age	 was	 directly	 associated	 with	 E/é-	ratio	 in	 both	 sexes	 (men,	
β = 0.020; women; β	=	0.048).	 A	 statistically	 significant	 interac-
tion	 term	 (age	*	sex	P	=	0.003)	 indicated	 a	more	 pronounced	 age	
effect	in	women	than	in	men	(Figure	1).	In	men,	one	SD	increase	in	
age	(ie,	5	years)	was	found	to	be	associated	with	~0.1	SD	increase	
in	E/é-	ratio	while	 the	 increase	was	~0.2	SD	 in	women	 (Figure	2).	
Furthermore,	similar	results	were	found	between	age	and	systolic	
blood	pressure:	a	more	pronounced	age	effect	was	found	in	women	
than	 in	men	 (β	=	0.78,	SE	=	0.082	 in	women;	β	=	0.38,	SE	=	0.089	
in	men).
In	 univariate	 regression	 analyses	 in	 the	 whole	 study	 popula-
tion,	E/é-	ratio	was	directly	associated	with	age,	LV	mass,	systolic	
blood	pressure,	diastolic	blood	pressure,	weight,	waist	circumfer-
ence,	BMI,	ALT,	GGT,	CRP,	 total	cholesterol,	 triglycerides,	 fasting	
serum	glucose,	insulin,	HOMA-	IR,	hypertension,	and	the	metabolic	
syndrome,	and	inversely	with	height	(Figure	2).	Additionally,	among	
women,	E/é-	ratio	was	directly	associated	with	heart	rate,	BSA	and	
alcohol	consumption	and	inversely	associated	with	glomerular	fil-
tration rate.
The	 results	 of	multivariate	 linear	 regression	 analyses	 for	 E/é-	
ratio,	 E/A-	ratio	 and	 LAVi	 are	 shown	 in	 Table	1,	 for	 septal	 é	 and	
lateral	é	the	results	are	shown	in	Table	S2.	In	the	analyses	for	E/é-	
ratio,	female	sex,	age,	systolic	blood	pressure,	waist	circumference,	
ALT,	and	smoking	were	directly	associated	with	E/é-	ratio,	whereas	
an	inverse	association	was	found	for	height.	Additionally,	LV	mass	
tended	 to	 associate	 directly	with	 E/é-	ratio	 (P	=	0.08).	No	 statisti-
cally	 significant	 multivariable	 associations	 were	 found	 for	 other	
determinants.	 In	 the	 analyses	 for	 E/A-	ratio,	 age,	 systolic	 blood	
pressure,	and	waist	circumference	were	 inversely	associated	with	
E/A-	ratio,	whereas	female	sex,	LV	mass,	and	physical	activity	were	
directly	 associated	 with	 E/A-	ratio.	 LAVi	 was	 directly	 associated	
with	 age,	 systolic	 blood	 pressure,	 LV	 mass,	 glomerular	 filtration	
rate,	and	physical	activity.
To	gain	further	insights	of	associations	between	the	indicators	of	
glucose	metabolism	and	LV	diastolic	function,	we	conducted	multi-
variate	analyses	replacing	fasting	serum	glucose	by	insulin.	In	such	
models,	 insulin	 was	 inversely	 associated	 with	 E/A-	ratio	 and	 LAVi	
(P	<	0.005	for	both),	whereas	no	association	was	found	for	E/é-	ratio	
(P	=	0.6).	When	systolic	blood	pressure,	waist	 circumference,	 total	
cholesterol,	 and	 fasting	 serum	glucose	were	 replaced	with	 the	di-
agnosis	 of	 the	metabolic	 syndrome	 in	 the	multivariate	model,	 the	
metabolic	 syndrome	 was	 found	 to	 have	 a	 significant	 association	
with	 higher	 E/é-	ratio	 (unadjusted	 mean	 values	 between	 groups:	
5.05	±	1.02	 vs	 4.74	±	1.02)	 and	 lower	 E/A-	ratio	 (1.40	±	0.32	 vs	
1.59	±	0.41)	 (multivariate	P	<	0.005	 for	 both),	whereas	no	 associa-
tion	was	found	for	LAVi	(22.79	±	6.56	vs	22.49	±	6.39)	(P	=	0.2).
The	 results	 from	 the	 analyses	 comparing	 each	 specific	 cardiac	
remodeling	 group	 (ie,	 concentric	 hypertrophy,	 eccentric	 hypertro-
phy	 and	 concentric	 remodeling)	 to	 the	 normal	 cardiac	 geometry	
group	are	shown	in	Figure	3.	The	study	participants	with	concentric	
hypertrophy	 had	 the	 highest	mean	E/é-	ratio	 values.	 Furthermore,	
compared	 to	 participants	 with	 normal	 cardiac	 geometry,	 partici-
pants	with	concentric	hypertrophy	had	a	higher	mean	systolic	blood	
pressure	(118	±	13.8	vs	125	±	16.3	mm	Hg,	P	=	0.016).	Additionally,	
E/é-	ratio	 correlated	 significantly	 with	 the	 following	 cardiac	 mea-
surements:	deceleration	time,	LV	diastolic	volume,	LA	systolic	vol-
ume,	relative	wall	thickness,	and	diastolic	posterior	wall-	and	septum	
thickness.	 (Table	S3).	 No	 statistically	 significant	 correlations	 were	
observed	between	E/é-	ratio	and	LAVi,	E/A-	ratio,	ejection	fraction,	
LV	diastolic	diameter,	LV	mass/BSA	or	LV	mass.
F IGURE  2 Sex-	specific	normalized	β-	estimates	for	the	
associations	between	E/é-	ratio	and	each	separate	study	variable.	
Sex-	stratified	univariate	linear	regression	analyses	were	adjusted	
for	study	centers,	and	variables	were	standardized	(0–1).	Error	bars	
denote	95%	confidence	intervals.	*Variable	log-	transformed	prior	to	
modeling.	ALT	=	alanine	aminotransferase;	BMI	=	body	mass	index;	
BSA	=	body	surface	area;	CRP	=	C-	reactive	protein;	GGT	=	gamma-	
glutamyltransferase;	HDL-	C	=	high-	density	lipoprotein	cholesterol;	
HOMA-	IR	=	Homeostasis	model	assessment-	estimated	insulin	
resistance;	LDL-	C	=	low-	density	lipoprotein	cholesterol;	LV	=	left	
ventricle
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4  | DISCUSSION
Our	 study	 revealed	 several	 potential	 determinants	 of	 impaired	 LV	
diastolic	 function	 in	a	population	of	34–49-	year-	old	 individuals.	 In	
addition	 to	 aging,	 strong	 links	were	 seen	with	metabolic	markers,	
such	as	blood	pressure	and	waist	circumference.	The	results	suggest	
that	individuals	with	cardio-	metabolic	risk	factors	may	be	at	risk	for	
developing	LV	diastolic	dysfunction.	In	addition	to	these	metabolic	
markers,	we	identified	female	sex,	shorter	stature,	liver	enzyme	ALT	
and	smoking	as	risk	factors	for	impaired	diastolic	LV	function	in	this	
age	group.	 Interestingly,	 the	association	between	age	and	LV	dias-
tolic	function	was	stronger	in	women	than	in	men,	suggesting	that	
women's	 LV	diastolic	 function	may	be	more	 vulnerable	 to	 the	 ad-
verse	effects	of	aging	than	men's.	In	both	sexes,	the	systolic	blood	
pressure	was	inversely	and	strongly	associated	with	LV	function	al-
ready	within	normal	or	mildly	elevated	systolic	blood	pressure	levels.	
Our	results	are	thus	well	in-	line	with	the	previous	studies	which	have	
demonstrated	that	elevated	blood	pressure	a	risk	factor	for	LV	dias-
tolic	dysfunction.4,18	As	an	example,	a	previous	study	by	Perkiömäki	
et	al,19	identified	elevated	systolic	blood	pressure	as	the	main	deter-
minant	predicting	LV	diastolic	dysfunction	during	20-	year	follow-	up	
in	a	middle-	aged	population.
Additionally,	we	observed	higher	E/é-	ratios	in	participants	with	
concentric	hypertrophy	than	in	participants	with	normal	cardiac	ge-
ometry.	Compared	to	the	participants	with	normal	cardiac	geometry,	
participants	with	concentric	hypertrophy	had	higher	mean	systolic	
blood	pressure.	Higher	E/é-	ratio	also	tended	to	associate	with	higher	
LV	mass.	If	ignored,	these	changes	may	lead	to	increased	mortality	
or	 sudden	 death.20	Our	 results	 are	 in-	line	with	 previous	 observa-
tions	that	have	shown	that	LV	hypertrophy	is	associated	with	lower	
LV	diastolic	 function.21,22	Previously,	 concentric	hypertrophy,	with	
reduced	LV	relaxation	and	worse	LV	volume-	mass,	associated	with	
lower	LV	diastolic	 function	 in	population	 study	with	a	high	preva-
lence	of	obesity	(44%).22	Our	results	suggest	that	concentric	hyper-
trophy	associates	similarly	with	LV	diastolic	function	in	a	population	
with	a	markedly	lower	prevalence	of	obesity.
In	our	study,	higher	age	and	 female	sex	were	 important	deter-
minants	 of	 higher	 E/é-	ratio.	 Previous	 studies	 in	 elderly	 popula-
tions	have	also	 indicated	that	diastolic	LV	function	decreases	with	
age.19,23	Several	mechanisms	have	been	proposed	to	be	implicated	
in	the	age-	related	LV	diastolic	function	decrease.	These	may	include	
an	increase	of	myocardial	fibrosis,	an	increase	of	myocyte	stiffness,	
changes	 in	 intra-	cellular	 calcium	 homeostasis,	 progressive	 thick-
ening	of	 LV	walls	 during	 aging,	 and	mitochondrial	 oxidative	 stress	
which	plays	a	central	role	in	cardiac	aging.24	Regarding	the	sex	dif-
ference,	previous	investigations	have	reported	that	the	prevalence	
of	heart	failure	with	preserved	ejection	fraction	and	LV	diastolic	dys-
function	is	higher	in	women	than	in	men.23,25	Previously,	it	has	been	
suggested	that	the	lack	of	estrogen	may	cause	impaired	LV	function	
in	postmenopausal	women.23	Our	novel	data	 suggest	 that	 the	sex	
difference	 in	diastolic	LV	function	starts	 to	emerge	already	during	
the	3rd	and	4th	decade	of	life,	that	is,	before	menopause,	and	that	in	
women	diastolic	function	declines	faster	by	age	than	in	men	already	
after	the	age	of	40.	The	underlying	pathophysiological	mechanisms	
TABLE  1 Results	of	multivariate	linear	regression	analyses
E/é E/A LAVia
β- estimate SE P- value β- estimate SE P- value β- estimate SE P- value
Female	sex 0.443 0.081 <0.005 0.099 0.034 <0.005 −0.465 0.496 0.348
Age	(years) 0.019 0.006 <0.005 −0.016 0.002 <0.005 0.121 0.041 <0.005
LV	mass	(g) 0.002 0.001 0.081 0.001 0.000 <0.005 0.050 0.006 <0.005
Systolic	blood	pressure	(mm	Hg) 0.011 0.002 <0.005 −0.004 0.001 <0.005 0.044 0.012 <0.005
Height	(cm) −0.018 0.004 <0.005 0.002 0.002 0.289
Waist	circumference	(cm) 0.005 0.002 0.024 −0.006 0.001 <0.005
Glomerular	filtration	rate	(mL/
min/1.73 m2)
−0.004 0.005 0.443 −0.001 0.002 0.582 0.123 0.037 <0.005
ALTb	(U/I) 0.100 0.047 0.032 −0.031 0.020 0.107 −0.471 0.313 0.133
Total	cholesterol	(mmol/L) 0.005 0.024 0.836 −0.015 0.010 0.128 −0.146 0.166 0.380
Fasting	serum	glucoseb	(mmol/L) 0.146 0.186 0.434 −0.065 0.078 0.406 −2.479 1.326 0.062
Smoking	(yes/no) 0.140 0.064 0.028 −0.022 0.027 0.400 0.219 0.444 0.623
Alcohol	consumptionc 0.011 0.021 0.604 0.010 0.009 0.267 0.140 0.145 0.334
Leisure-	time	physical	activity	
indexd
0.002 0.012 0.888 0.014 0.005 <0.005 0.429 0.082 <0.005
ALT	=	alanine	aminotransferase;	LAVi	=	left	atrial	volume	index;	LV	=	left	ventricle;	SE	=	standard	error.
aHeight	and	waist	were	not	included	in	the	model.	
bLog-	transformed	prior	to	modeling.	
cAlcohol	consumption	measured	as	drinks	per	day.	
dAn	index	score	ranging	between	5–15.
Additionally,	to	the	variables	shown	in	the	table,	study	center	was	included	as	an	independent	variable	in	the	models.	
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creating	the	sex	difference	is	most	likely	multifactorial,	and	not	due	
only	to	the	loss	of	the	cardioprotective	effects	of	estrogens.
Active	 smoking	was	 associated	with	 lower	 LV	 function	 inde-
pendent	of	the	other	determinants.	Previous	studies	have	shown	
an	association	between	smoking	and	a	higher	risk	for	the	incidence	
of	heart	 failure	 independent	of	coronary	artery	disease.26 In the 
study	by	Nadruz	et	al,27	active	smoking	and	cumulative	cigarette	
exposure	were	associated	with	subtle	alterations	 in	LV	structure	
and	 function	 in	 a	 population	 aged	 45–64	years.	 Additionally,	
Bennet	et	al28	have	reported	an	association	between	smoking	and	
LV	diastolic	dysfunction	in	women.	The	adverse	effects	of	tobacco	
on	the	myocardium	could	be	driven	by	smoking-	induced	increases	
in	arterial	stiffness	and	increase	of	LV	mass.27,29	 It	has	also	been	
hypothesized	 that	 increased	 blood	 pressure	 or	 other	 coexisting	
risk	factors,	such	as	alcohol	consumption	or	lower	physical	activity	
level,	could	confound	smoking-	associated	decrease	on	LV	diastolic	
function.27,28	However,	 our	 results	 do	 not	 support	 confounding.	
We	were	able	to	take	into	account	a	wide	array	of	potential	con-
founders	 and	 still	 smoking	 remained	 independently	 associated	
with	a	lower	diastolic	function.
In	 the	present	study,	metabolic	 syndrome	was	 found	 to	be	as-
sociated	with	E/é-	and	E/A-	ratios,	as	seen	 in	previous	studies.30,31 
In	addition,	E/é-	ratio	was	directly	associated	with	liver	enzyme	ALT,	
which	may	become	elevated,	for	example,	in	the	fatty	liver	disease.32 
The	metabolic	syndrome	is	a	clustering	of	metabolic	and	cardiovas-
cular	risk	factors,	and	fatty	liver	disease	is	considered	to	be	the	he-
patic	manifestation	of	the	metabolic	syndrome.	Both	the	metabolic	
syndrome	and	 fatty	 liver	disease	are	associated	with	 cardiovascu-
lar	disease,	as	well	as	alterations	in	cardiac	structure,	function,	and	
metabolism.30,31,33	The	precise	mechanisms	by	which	the	metabolic	
syndrome	and	fatty	liver	disease	cause	abnormal	of	LV	diastolic	func-
tion	are	unknown,	and	the	proposed	mechanisms	associate	addition-
ally	to	multiple	other	comorbidities.34,35	Our	population-	based	data	
demonstrating	 an	 independent	 association	 between	 elevated	 ALT	
and	LV	diastolic	 function	 suggest	 that	hepatic	manifestations	may	
play	a	 role	or	 coincide	with	 the	development	of	LV	diastolic	 func-
tion.	Our	 data	 also	 indicated	 that	 the	 link	 between	 the	metabolic	
syndrome	and	LV	diastolic	function	was	driven	by	elevated	systolic	
blood	pressure	and	waist	circumference,	as	the	other	components,	
such	as	lipids	and	glucose,	showed	no	associations	with	LV	function.
The	 other	 indicators	 of	 LV	 function,	 including	 E/A-	ratio	 and	
LAVi	were	inversely	associated	with	insulin	and	directly	with	phys-
ical	activity,	whereas	these	associations	were	not	detected	for	the	
E/é-	ratio.	 In	the	study	by	Hwang	et	al,30	 insulin	resistance	was	as-
sociated	 with	 impaired	 LV	 diastolic	 function	 in	 a	 Korean	 popula-
tion,	and	stronger	effects	were	seen	for	E/A-	ratio	than	E/é-	ratio.	In	
several	previous	studies,	insulin	resistance	and	diabetes	have	been	
shown	 to	be	 linked	with	alterations	 in	 cardiac	 structure	and	 func-
tion.36,37	Several	 factors	may	explain	 the	structural	and	functional	
changes,	 including	hyperglycemia,	 coronary	microvascular	disease,	
autonomic	 neuropathy,	 altered	 cardiac	 progenitor	 cell	 function,	
and	renin-	angiotensin-	aldosterone	system	activation.36	The	precise	
pathophysiologic	mechanisms	behind	these	links,	however,	are	not	
understood.	 Furthermore,	 both	 E/A-	ratio	 and	 LAVi	 were	 signifi-
cantly	associated	with	physical	activity,	which	 is	previously	known	
to	cause	alterations	in	cardiac	structure,	and	enlargement	of	LA.38 
Our	 results	 are	 in-	line	 with	 varied	 results	 from	 previous	 studies	
where	no	association	was	found	between	E/é-	ratio	and	physical	ac-
tivity	in	a	middle-	aged	population,	but	in	an	elderly	population	ideal	
level	of	physical	activity	was	associated	favorably	with	LV	diastolic	
function.39,40
There	 are	 some	 limitations	 in	 our	 study	 that	 need	 to	 be	 dis-
cussed.	One	potential	limitation	is	a	possible	selection	of	the	study	
population.	As	in	every	longitudinal	study,	there	is	a	loss	to	follow-	up	
in	 the	YFS.	However,	 detailed	 assessments	 of	 the	 representative-
ness	have	previously	demonstrated	that	there	are	no	significant	dif-
ferences	 between	 the	participants	 and	nonparticipants	 in	 the	 age	
and	sex-	adjusted	analyses.5,41	The	YFS	population	is	racially	homo-
geneous,	therefore	our	results	are	generalizable	to	white	Caucasian	
F IGURE  3 Least-	squares	means	of	E/é-	ratio	in	different	cardiac	
remodeling	groups.	Error	bars	denote	95%	confidence	intervals.	
CH	=	concentric	hypertrophy	(n	=	40),	CR	=	concentric	remodeling	
(n	=	229),	EH	=	eccentric	hypertrophy	(n	=	234),	NG	=	normal	
cardiac	geometry	(n	=	1353).	P-	values	compared	to	NG	group	
displayed	at	the	bottom	of	each	bar.	Model	adjusted	with	study	
center,	sex,	and	age.	Corresponding	results	were	seen	with	
unadjusted	mean	values.	The	LV	geometry	groups	were	defined	by	
the	population	85th	percentile	cut-	offs	values	for	LV	hypertrophy	
(indexed	LV	mass/BSA)	and	relative	wall	thickness
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populations.	 Furthermore,	 since	 the	 LV	 function	 and	 LV	 structure	
measurements	have	been	measured	thus	far	only	once	in	our	cohort,	
we	were	 not	 able	 to	 evaluate	 longitudinal	 changes	 in	 LV	 diastolic	
function	or	LV	hypertrophy	in	our	population.	Future	follow-	ups	is	
needed	 to	provide	 insights	 on	whether	 the	 LV	 function	measured	
in	asymptomatic	 individuals	 is	of	value	 in	predicting	which	part	of	
our	 study	 population	 will	 develop	 clinically	 relevant	 LV	 diastolic	
dysfunction	or	 a	 heart	 failure.	 E/é-	ratio	 is	 the	 best	 available	 non-
invasive	 predictor	 for	 the	 evaluation	 of	 LV	 end-	diastolic	 pressure,	
but	it	is	not	a	consistent	indicator	of	LV	filling	pressures	in	individ-
ual	patients	in	specific	clinical	situations.42	However,	at	a	population	
level	in	healthy	subjects	E/é-	ratio	has	been	shown	to	associate	with	
an	increased	incidence	of	heart	failure	and	has	been	used	in	multi-
ple	studies	to	predict	all-	cause	mortality,	cardiovascular	death,	and	
heart	failure	hospitalizations	in	several	disease	states.43–47	E/é-	ratio	
includes	the	tissue	Doppler	measurement	of	mitral	annular	early	di-
astolic	velocity	(é)	and	thus	can	be	considered	to	reflect	changes	in	
the	myocardial	movement	more	directly	than	measurement	of	E/A-	
ratio	or	LAVi.2	E/A-	ratio	and	LAVi	are	being	shown	to	be	affected	by	
physical	activity	and	this	was	also	shown	to	be	confounding	factor	
in	our	model	as	we	studied	healthy	volunteers.38	Notably,	we	failed	
to	detect	associations	with	insulin	and	physical	activity	for	E/é-	ratio.	
Finally,	to	study	the	associations	of	cardiac	remodeling	on	diastolic	
function,	we	defined	the	remodeling	phenotypes	by	using	the	pop-
ulation	85th	cut-	offs	values	for	LV	mass	and	relative	wall	thickness.	
Therefore,	the	number	of	individuals	in	the	various	remodeling	cate-
gories	is	higher	than	it	would	have	been	by	using	the	clinical	criteria	
of	LV	remodeling	phenotypes	based	on	ASE	and	EACVI	guideline.6 
For	example,	there	were	no	individuals	in	our	study	population	that	
fulfilled	the	clinical	diagnoses	of	concentric	hypertrophy.	However,	
by	using	an	arbitrary	extreme	cut-	point	based	on	population	distri-
bution,	we	are	able	 to	show	significant	differences	on	LV	diastolic	
function	between	cardiac	remodeling	groups	suggesting	that	the	re-
modeling	phenomenon	is	linked	to	diastolic	function	before	reaching	
clinical	diagnostic	criteria.
In	summary,	all	studied	echocardiographic	LV	diastolic	function	
indices	were	robustly	associated	with	age	and	systolic	blood	pres-
sure	in	the	34–49-	year-	old	participants	of	the	YFS.	In	addition,	we	
found	evidence	that	waist	circumference,	smoking	and	physical	ac-
tivity	could	be	modifiable	determinants	of	the	LV	function.	Thus,	our	
results	support	active	and	early	on	interventions	focusing	on	the	im-
plementation	of	a	healthy	lifestyle	during	the	whole	lifespan	in	order	
to	promote	LV	diastolic	function.
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